Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice

Summary

Dabigatran etexilate is a new oral anticoagulant recently approved in Europe for the prevention of stroke or systemic embolism in adult patients with non-valvular atrial fibrillation (AF) and at least one risk factor for stroke. With a fast onset of action and a predictable anticoagulant effect obviating the need for coagulation monitoring, dabigatran etexilate offers practical advantages over vitamin K antagonists in clinical practice. However, clinicians may have questions about practical aspects of dabigatran etexilate use including monitoring anticoagulant efficacy, interruption for surgical or invasive procedures and management of bleeding. This review article aims to address these concerns and provide guidance on the use of dabigatran etexilate in special situations, such as acute coronary syndromes and cardiac revascularisation. In addition, cut-off values for different coagulation assay results associated with an increased risk of bleeding are given.

Note: The editorial process for this article was fully handled by Prof. Christian Weber, Editor-in-Chief.

Keywords

Dabigatran - atrial fibrillation - oral anticoagulant - bleeding

• References

• 1 Camm AJ, Kirchhof P, Lip GY. et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429.
• 2 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
• 3 Mant J, Hobbs FD, Fletcher K. et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493-503.
• 4 Dewilde S, Carey IM, Emmas C. et al. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart 2006; 92: 1064-1070.
• 5 European Medicines Agency. Pradaxa. Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf Accessed, 25 November 2011
• 6 U.S. Food and Drug Administration. Pradaxa^® Prescribing Information. Nov 2011 Available at: www.pradaxa.com/ Accessed, 25 November 2011
• 7 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
• 8 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363: 1875-1876.
• 9 Blech S, Ebner T, Ludwig-Schwellinger E. et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36: 386-399.
• 10 Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
• 11 Legrand M, Mateo J, Aribaud A. et al. The use of dabigatran in elderly patients. Arch Intern Med 2011; 171: 1285-1286.
• 12 van Ryn J, Stangier J, Haertter S. et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-11127.
• 13 Baruch L, Sherman O. Potential inaccuracy of Point-of-Care INR in dabigatrantreated patients. Ann Pharmacother 2011; 45: e40.
• 14 van Ryn J, Baruch L, Clemens A. Interpretation of point-of-care INR results in patients treated with dabigatran. Am J Med. 2012 in press.
• 15 Lindahl TL, Baghaei F, Blixter IF. et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011; 105: 371-378.
• 16 Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis. 2012 epub ahead of print.
• 17 European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) Assessment Report for Pradaxa. 9 June 2011 Available from //www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000829/WC500110875.pdf Accessed, 24 November 2011
• 18 Stangier J, Rathgen K, Stähle H. et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49: 259-268.
• 19 van Ryn J, Litzenburger T, Waterman A. et al. Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models (abstract). J Am Coll Cardiol 2011; 57 (Suppl. 01) E1130.
• 20 Lu G, Deguzman FR, Karbarz MJ. et al. Reversal of rivaroxaban mediated anticoagulation in animal models by a recombinant antidote protein (r-Antidote, PRT064445) (Abstract 3712). Eur Heart J 2011; 32: 640-641.
• 21 Zeitler SH, Pragst I, Doerr B. et al. Beriplex P/N restores haemostasis after dabig-atran overdosing in an acute rabbit bleeding model (abstract 1023). 16^th World Congress on Heart Disease, Annual Scientific Sessions 2011. Vancouver, BC, Canada: July, 23-26 2011
• 22 Eerenberg ES, Kamphuisen PW, Sijpkens MK. et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579.
• 23 CSL Behring Canada Inc. Product monograph Beriplex® P/N (Human prothrombin complex. Nov 5 2010 Available at: http://www.cslbehring.ca/docs/17/83/Beriplex_NC134547_eng_app5nov10-ar.pdf Accessed, 24 November 2011
• 24 van Ryn J, Schurer J, Kink-Eiband M. et al. The successful reversal of dabigatraninduced bleeding by coagulation factor concentrates in a rat tail bleeding model do not correlate with ex vivo markers of anticoagulation (Abstract 2316). Blood 2011; 118.
• 25 van Ryn J, Neubauer M, Flieg R. et al. Successful removal of dabigatran in flowing blood with an activated charcoal hemoperfusion column in an in vitro test system (abstract P485). Pathophysiol Haemost Thromb 2010; 57 (Suppl. 01) A94.
• 26 Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 2011; 123: 1436-1450.
• 27 Adams Jr HP, del Zoppo G, Alberts MJ. et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/ American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Circulation 2007; 115: e478-e534.
• 28 Seet RC, Zhang Y, Moore SA. et al. Subtherapeutic international normalized ratio in warfarin-treated patients increases the risk for symptomatic intracerebral hemorrhage after intravenous thrombolysis. Stroke 2011; 42: 2333-2335.
• 29 De Smedt A, De Raedt S, Nieboer K. et al. Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran. Cerebrovasc Dis 2010; 30: 533-534.
• 30 Matute MC, Guillan M, Garcia-Caldentey J. et al. Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran. Thromb Haemost 2011; 106: 178-179.
• 31 Weimar C, Hohnloser SH, Eikelboom JW. et al. Preventing cardioembolic stroke in atrial fibrillation with dabigatran. Curr Neurol Neurosci Rep. 2011 epub ahead of print.
• 32 Leebeek FWG, de Maat M P, Jones R. et al. Randomized, open-label, dose-ranging study of dabigatran, a novel, oral, direct thrombin inhibitor, in elective PCI (the D-fine study) (abstract O-TH-032). J Thromb Haemost 2011; 09 (Suppl. 02) 731.
• 33 Lip GY, Huber K, Andreotti F. et al. European Society of Cardiology Working Group on Thrombosis. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 2010; 103: 13-28.
• 34 Faxon D P, Eikelboom JW, Berger PB. et al. Consensus Document: Antithrombotic therapy in patients with atrial fibrillation under going coronary stenting. A North-American perspective. Thromb Haemost 2011; 106: 572-584.
• 35 Eikelboom JW, Wallentin L, Connolly SJ. et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the Randomized Evaluation of Long-term anticoagulant Therapy (RE-LY) Trial. Circulation 2011; 123: 2363-2372.
• 36 Nagarakanti R, Ezekowitz MD, Oldgren J. et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011; 123: 131-136.
• 37 Winkle RA, Mead RH, Engel G. et al. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2011 epub ahead of print.
• 38 Blanc JJ, Almendral J, Brignole M. et al. Scientific Initiatives Committee of the European Heart Rhythm Association. Consensus document on antithrombotic therapy in the setting of electrophysiological procedures. Europace 2008; 10: 513-527.
• 39 Verma A, Macle L, Cox J, at el. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: catheter ablation for atrial fibrillation/atrial flutter. Can J Cardiol 2011; 27: 60-66.
• 40 Maegdefessel L, Linde T, Krapiec F. et al. In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves. Thromb Res 2010; 126: e196-e200.
• 41 McKellar SH, Abel S, Camp CL. et al. Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves. J Thorac Cardiovasc Surg 2011; 141: 1410-1416.
• 42 RE-ALIGN: A randomised, phase II study to evaluate the safety of oral dabigatran etexilate in patients after heart valve replacement. ClinicalTrials.gov Identifier: NCT01452347. Accessed at http://www.clinicaltrials.gov
• 43 Boehringer Ingelheim. Advisory Committee Briefing Document. Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterialsDrugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM226009.pdf Accessed, 27 November 2011
• 44 Diener HC, Grond M, Röther J. et al. Dabigatran for stroke prevention in patients with TIA or ischaemic stroke and atrial fibrillation: Practical apects. Akt Neurol 2011; 38: 261-266.
• 45 Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P. et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY trial. Circulation. 2012 epub ahead of print.
• 46 Raju NC, Hankey GJ. Dabigatran etexilate in people with atrial fibrillation. Br Med J 2010; 341: c3784.
• 47 Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: Meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012 epub ahead of print.
• 48 Kajubi SK. Additional monitoring tools to improve the quality of anticoagulation management. Arch Intern Med 2000; 160: 3006.
• 49 Reilly PA, Conrad CA, Faaij RA. et al. Concomitant use of P-glycoprotein inhibitors with dabigatran or warfarin in the RE-LY trial (abstract 129). Eur Heart J 2011; 32 (Suppl. 01) 6.
• 50 U.S. Food and Drug Administration - FDA Briefing Information, Dabigatran Etexilate Mesylate Capsules, for the September 20, 2010 Meeting of the Cardiovascular and Renal Drugs Advisory Committee. Oct 9th 2010 Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM247244.pdf Accessed, 24 November 2011
• 51 Dans AM, Ezekowitz M, Wallentin L. et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial (abstract 1161). Eur Heart J 2011; 32 (Suppl. 01) 6.
• 52 Pengo V, Crippa L, Falanga A. et al. Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 2011; 106: 868-876.
• 53 Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010; 104: 49-60.
• 54 Lip GY. Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at 'moderate risk' [CHADS2 score=1]: simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice. Thromb Haemost 2010; 103: 683-685.
• 55 Gorin L, Fauchier L, Nonin E. et al. Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1. Thromb Haemost 2010; 103: 833-40.
• 56 Pisters R, Lane DA, Nieuwlaat R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100.
• 57 Eriksson BI, Dahl OE, Huo MH. et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial. Thromb Haemost 2011; 105: 721-729.
• 58 Brunet A, Hermabessiere S, Benain X. Pharmacokinetic and pharmacodynamic interaction of dronedarone and dabigatran in healthy subjects (abstract P3566). Eur Heart J 2011; 32 (Suppl. 01) 618-619.